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Abstract
Adenomatoid tumors are the most common neoplasm of the epididymis, and histologically similar 
adenomatoid tumors also commonly arise in the uterus and fallopian tube. To investigate the 
molecular pathogenesis of these tumors, we performed genomic profiling on a cohort of 31 
adenomatoid tumors of the male and female genital tracts. We identified that all tumors harbored 
somatic missense mutations in the TRAF7 gene, which encodes an E3 ubiquitin ligase belonging 
to the family of tumor necrosis factor receptor-associated factors (TRAFs). These mutations all 
clustered into one of five recurrent hotspots within the WD40 repeat domains at the C-terminus of 
the protein. Functional studies in vitro revealed that expression of mutant but not wildtype TRAF7 
led to increased phosphorylation of nuclear factor-kappa B (NF-kB) and increased expression of 
L1 cell adhesion molecule (L1CAM), a marker of NF-kB pathway activation. 
Immunohistochemistry demonstrated robust L1CAM expression in adenomatoid tumors that was 
absent in normal mesothelial cells, malignant peritoneal mesotheliomas, and multilocular 
peritoneal inclusion cysts. Together, these studies demonstrate that adenomatoid tumors of the 
male and female genital tract are genetically defined by TRAF7 mutation that drives aberrant NF-
kB pathway activation.
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INTRODUCTION
Adenomatoid tumors are the most common neoplasm of the epididymis where they typically 
present as small, painless extra-testicular masses in young or middle age adults and are often 
diagnosed after orchiectomy. Histologically similar tumors also arise in the uterus and 
fallopian tube, which are also called adenomatoid tumors given their presumed relatedness. 
Adenomatoid tumors in women are similarly found in young or middle age adults where 
they are most often discovered incidentally during hysterectomy or salpingectomy for other 
clinical indications such as endometrial cancer, ovarian cancer, or uterine leiomyomas. Apart 
from rare examples, adenomatoid tumors exhibit a benign clinical course without recurrence 
after resection and do not require additional therapy. Microscopically, they are poorly 
circumscribed neoplasms composed of a variable population of cuboidal to flattened cells 
with prominent cytoplasmic vacuolization arranged in cords with numerous cystically 
dilated spaces simulating vascular channels. The intervening stroma often contains abundant 
smooth muscle and elastic fibers and may have a prominent lymphocytic inflammatory 
infiltrate. Adenomatoid tumors of the male and female genital tract are presumed to be of 
mesothelial origin based on their morphological and ultrastructural features, as well as 
expression of markers typical of mesothelial cells and mesotheliomas including calretinin, 
WT1, D2–40, and cytokeratin.1–6
The molecular pathogenesis of these relatively common tumors of the male and female 
genital tract is unknown. Of note is a growing number of case reports documenting an 
association of adenomatoid tumors arising in patients who are immunosuppressed for 
treatment of autoimmune disease or following allograft organ transplantation, and rare 
examples of immunosuppressed patients with giant or multiple adenomatoid tumors have 
also been reported.7–11 This suggests a potential link between adenomatoid tumors and 
deregulated cytokine signaling pathways within mesothelial cells. Herein, we report the 
discovery of a defining genetic cause of adenomatoid tumors that may help to explain this 
association of adenomatoid tumors with immune dysregulation.
MATERIALS AND METHODS
Study population and tumor specimens
This study was approved by the Institutional Review Board of the University of California, 
San Francisco. Thirty one adenomatoid tumors from a cohort of 28 patients were retrieved 
from the pathology archives of our institution, spanning years 1994 to 2016. All tumor 
specimens had been fixed in 10% neutral-buffered formalin and embedded in paraffin. 
Paraffin embedded blocks of adjacent uninvolved testis, fallopian tube, or uterus were also 
retrieved for each patient. Pathologic review of all tumor samples was performed to confirm 
the diagnosis by N.M.J., K.G., J.T.R., C.Z., and D.A.S.
Targeted next-generation DNA sequencing and mutational analysis
Tumor tissue and uninvolved testis, fallopian tube, or uterus was macrodissected from 
formalin-fixed, paraffin-embedded blocks for the 28 patients. Genomic DNA was extracted 
from the macrodissected tissue using the QIAamp DNA FFPE Tissue Kit (Qiagen) 
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according to the manufacturer’s protocol. Capture-based next-generation DNA sequencing 
was performed at the University of California, San Francisco Clinical Cancer Genomics 
Laboratory, using an assay that targets all coding exons of 479 cancer-related genes, select 
introns of 47 genes, and TERT promoter with a total sequencing footprint of 2.8 Mb 
(UCSF500 Cancer Panel; Supplemental Table 3).12 Sequencing libraries were prepared from 
genomic DNA, and target enrichment was performed by hybrid capture using a custom 
oligonucleotide library (Roche NimbleGen). Sequencing was performed on an Illumina 
HiSeq 2500. Duplicate sequencing reads were removed computationally to allow for 
accurate allele frequency determination and copy number calling. The analysis was based on 
the human reference sequence (NCBI build 37) using the following software packages: 
BWA: 0.7.13, Samtools: 1.1 (using htslib 1.1), Picard tools: 1.97 (1504), GATK: Appistry 
v2015.1.1-3.4.46-0-ga8e1d99, CNVkit: 0.7.2, Pindel: 0.2.5b8, SATK: Appistry v2015.1.1-1-
gea45d62, Annovar: v2016Feb01, Freebayes: 0.9.20, and Delly: 0.7.2.13–20 Single 
nucleotide variants and insertions/deletions were visualized and verified using Integrated 
Genome Viewer. Genome-wide copy number analysis based on on-target and off-target 
reads was performed by CNVkit and Nexus Copy Number (Biodiscovery).16
TRAF7 cDNA expression vector construction and site-directed mutagenesis
A human wildtype TRAF7 cDNA (CCDS10461) with flanking 5′ BamHI and 3′ EcoRI 
restriction sites was synthesized by GenScript and cloned into the pCDF1-MCS2-EF1-Puro 
expression vector (System Biosciences). p.H521R, p.S561R, and Y538S mutations were 
engineered into the pCDF1-TRAF7 construct by site-directed mutagenesis using the 
QuikChange II XL kit (Stratagene) as directed by the manufacturer. The coding sequence of 
all expression vectors was verified by Sanger sequencing. Primer sequences used for the 
mutagenesis reactions were as follows:
TRAF7 H521R Fwd: 5′-CTCACAGGCCTCAACCGCTGGGTGCGGGCCCTG -3′
TRAF7 H521R Rev: 5′-CAGGGCCCGCACCCAGCGGTTGAGGCCTGTGAG -3′
TRAF7 S561R Fwd: 5′-GACGTCTGGTGGCAGGGTCTACTCCATTGCTG -3′
TRAF7 S561R Rev: 5′-CAGCAATGGAGTAGACCCTGCCACCAGACGTC -3′
TRAF7 Y538S Fwd: 5′-CTGTACAGCGGCTCCTCCCAGACAATCAAGATC -3′
TRAF7 Y538S Rev: 5′-GATCTTGATTGTCTGGGAGGAGCCGCTGTACAG -3′.
Cell culture and transfections
293T cells were obtained directly from ATCC and were maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum at 37°C in 5% CO2. 
Empty pCDF1 vector or pCDF1-TRAF7 wildtype and mutant expression vectors were 
transfected into 293T cells using Fugene 6 (Roche) as described by the manufacturer.
Western blot
Protein was extracted from 293T cells in RIPA buffer at 48 hours after transfection, resolved 
by SDS-PAGE, and immunoblotted following standard biochemical techniques. Primary 
antibodies used were phospho-NF-kB p65 Ser536 (Cell Signaling, clone 7F1), total NF-kB 
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p65 (Cell Signaling, clone D14E12), L1CAM (Sigma, clone UJ127.11), and β-actin (Sigma, 
clone AC-15).
Immunohistochemistry
Immunohistochemistry was performed on whole formalin-fixed, paraffin-embedded tissue 
sections using anti-L1CAM antibodies (Sigma, clone UJ127.11) at a 1:1800 dilution 
following antigen retrieval. All immunostaining was performed in a Ventana Benchmark 
automated stainer. Diaminobenzidine was used as the chromogen, followed by hematoxylin 
counterstain. This immunohistochemistry was performed on 8 cases of adenomatoid tumor 
of the genital tract with confirmed somatic TRAF7 mutation, 7 cases of normal mesothelial 
cells lining organs of the peritoneal cavity (4 from ovarian surface and 3 from fallopian tube 
surface), 7 cases of malignant peritoneal mesothelioma, and 6 cases of multilocular 
peritoneal inclusion cyst. All specimens were from the pathology archives of our institution 
and had been fixed in 10% neutral-buffered formalin and embedded in paraffin. We have 
previously reported the clinical, histopathologic, and molecular features for this cohort of 
malignant peritoneal mesotheliomas.12
RESULTS
Clinicopathologic features of the adenomatoid tumor patient cohort
In order to study the molecular pathogenesis of adenomatoid tumors of the male and female 
genital tracts, we assembled a cohort of matched tumor and normal tissue for 31 
adenomatoid tumors from 28 patients for genomic analysis. The clinical features of this 
patient cohort are listed in Table 1. The 7 male and 21 female patients ranged in age from 
31–72 years (median 47 years). The 7 male patients all had tumors located in the 
epididymis. The 21 female patients had tumors located in the fallopian tube (n=7) or uterus 
(n=17). The 7 male patients all underwent total or partial orchiectomy for a painless 
testicular mass. The majority of the tumors in the 21 females were discovered incidentally 
upon hysterectomy or salpingectomy for other pathologic processes or elective tubal 
ligation. Ten of the 25 patients (40%) with available clinical history had a history of immune 
dysregulation, which included autoimmune disease, HIV infection, or immunosuppressive 
medical therapy following allograft organ transplantation. Tumors ranged in size from 1 to 
15 cm (mean 2.3 cm). One exceptional female (patient #14) who was immunosuppressed 
following heart and lung transplant for congenital heart disease underwent hysterectomy and 
bilateral salpingo-oophorectomy at age 60 years and was found to have multiple distinct 
adenomatoid tumors, with one in the fallopian tube and three in the uterus. Another 
exceptional female (patient #15) who had systemic lupus erythematosus and was on 
immunosuppressive therapy following kidney transplant underwent hysterectomy for a giant 
adenomatoid tumor of the uterus (15 cm). After a median follow-up of approximately 12 
months, no patients in this cohort experienced disease recurrence.
Genomic analysis of adenomatoid tumors of the genital tract
Targeted next-generation sequencing was performed on genomic DNA isolated from the 31 
tumors, as well as matched normal tissue, as described in the Methods. This identified 
somatic missense mutations in the TRAF7 gene in all 31 tumors (Figs. 1–4, Supplemental 
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Table 1). Each tumor contained a single missense mutation in TRAF7, which encodes an E3 
ubiquitin ligase and is a member of the family of tumor necrosis factor receptor-associated 
factors (TRAFs). The mutations all clustered into one of five hotspots located in the WD40 
repeats at the C-terminus of the protein (Fig. 5). The most common mutation was p.S561R 
occurring in 13/31 tumors (42%) due to either a c.1683C>G (n=7) or c.1683C>A (n=6) 
substitution. The second most common mutation was p.H521R occurring in 11/31 tumors 
(35%) due to c.1562A>G substitution. Among the other seven tumors, three harbored 
p.Y538S mutation, three harbored p.Y577S, and one harbored p.L519P. These TRAF7 
missense mutations were verified to be somatic (i.e. tumor-specific) in all cases. The mutant 
allele frequency for the TRAF7 variants ranged from 1–34%. Cases with the highest TRAF7 
mutant allele frequencies had genomic DNA isolated from areas histologically visualized to 
contain a high tumor cell content. Cases with the lowest TRAF7 mutant allele frequency had 
genomic DNA that was isolated from tumors containing sparse tumor nuclei that were 
diffusely infiltrating the uterine myometrium. No chromosomal gains, losses, or copy-
neutral loss of heterozygosity involving the TRAF7 locus at chromosome 16p13.3 were 
identified in any of the tumors. Therefore, these data suggest that TRAF7 mutation is likely 
a clonal heterozygous alteration in adenomatoid tumors (i.e. present in all tumor cells), 
indicating that it is probably an early or initiating event in tumorigenesis.
In addition to TRAF7 mutation, 9/31 tumors (29%) contained somatic nonsynonymous 
mutations in at least one additional gene (Fig. 4, Supplemental Table 2). Two of the 31 
tumors (6%) contained a frameshift mutation in SETD2, which encodes a histone 
methyltransferase with specificity for lysine-36 of histone H3 and is recurrently mutated in 
renal cell carcinomas and pediatric gliomas.21,22 Two tumors contained missense mutations 
in LRP1B, which encodes a lipoprotein receptor-related protein. Two tumors contained 
missense mutations in MED12, a transcriptional co-activator that is recurrently mutated in 
uterine leiomyomas and breast fibroadenomas.23,24 One of the two MED12 mutations 
(p.L36R), found in a uterine adenomatoid tumor, localizes within an activating mutational 
hotspot that has been identified near the N-terminus of the protein. However, the possibility 
that this MED12 mutation represents contamination by an adjacent leiomyoma is a distinct 
possibility. No other genes sequenced in this cohort of 31 adenomatoid tumors contained 
recurrent genetic alterations (Supplemental Table 3). No chromosomal gains, losses, or focal 
amplifications or deletions were identified in any of the 31 tumors (Supplemental Fig. 1).
Sequencing of the four separate adenomatoid tumors in patient #14 identified different 
somatic TRAF7 mutations in each tumor, confirming that these anatomically distinct tumors 
were also genetically distinct (Fig. 6). No pathogenic alterations were identified in the 
germline of this immunosuppressed patient to account for the multiple adenomatoid tumors. 
In order to study potential intratumoral genetic heterogeneity, genomic DNA was isolated 
and sequenced from four different regions of the giant adenomatoid tumor in patient #15. 
All four regions contained the identical TRAF7 and LRP1B somatic mutations, and no 
private alterations were identified in any of the four regions, indicating that the TRAF7 and 
LRP1B variants were likely early or initiating events in this tumor.
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TRAF7 mutations drive aberrant NF-kB pathway activation
In order to study the functional effects of these recurrent TRAF7 mutations, we generated an 
expression vector for wildtype TRAF7, as well as three of the most common mutations 
observed in adenomatoid tumors (p.H521R, p.S561R, and p.Y538S). As TRAF7 belongs to 
the family of TNF receptor-associated factors that are known to regulate nuclear factor-
kappa B (NF-kB),25 we hypothesized that these recurrent TRAF7 mutations might cause 
adenomatoid tumors through deregulation of NF-kB signaling. Upon transfection of mutant 
but not wildtype TRAF7 into human embryonic 293T cells, we observed an increase in 
phosphorylation of the p65 subunit of NF-kB (Fig. 7), a post-translational modification 
associated with activation of NF-kB signaling.26,27 L1 cell adhesion molecule (L1CAM) is a 
known transcriptional target of NF-kB and has emerged as a reliable surrogate marker for 
tumors with activated NF-kB signaling.28,29 We observed a robust increase in levels of 
L1CAM protein in cells expressing mutant but not wildtype TRAF7 (Fig. 7). We therefore 
considered the possibility that TRAF7 mutations cause adenomatoid tumors of the genital 
tract by activation of NF-kB signaling.
To further assess this hypothesis, we performed immunohistochemistry for L1CAM protein 
on a series of adenomatoid tumors, as well as normal mesothelium and two other tumors of 
mesothelial origin – malignant peritoneal mesothelioma and multilocular peritoneal 
inclusion cyst, also known as benign multicystic mesothelioma. We observed strong 
membranous staining for L1CAM in all adenomatoid tumors (n=8) (Fig. 8, Supplemental 
Fig. 2, Table 2). In contrast, no appreciable L1CAM staining was seen in normal mesothelial 
cells lining organs of the peritoneal cavity (n=7), nor was staining seen in malignant 
peritoneal mesotheliomas (n=7) or multilocular peritoneal inclusion cysts (n=6) (Fig. 8 and 
Supplemental Figs. 3 and 4). Together, these data suggest that TRAF7 mutations lead to the 
development of adenomatoid tumors, at least in part, through activation of NF-kB signaling.
DISCUSSION
Our study identifies a defining genetic alteration in adenomatoid tumors of the genital tract, 
which was uniformly present in epididymal, uterine, and fallopian tube tumors. Thus, in 
addition to morphologic and immunophenotypic similarities, adenomatoid tumors of the 
epididymis in males and fallopian tube and uterus in females also share a common genetic 
basis, and therefore are all likely to be a single tumor entity.
In addition to adenomatoid tumors of the genital tract, TRAF7 mutations have been recently 
identified at high frequency in intraneural perineuriomas, a rare nerve sheath tumor derived 
from perineurial cells.30 Additionally, TRAF7 mutations have been identified in benign 
meningiomas, particularly those of the secretory variant and those located in the anterior 
skull base, where they uniformly occur with concurrent mutations in KLF4, AKT1, or 
PIK3CA.31,32 Alterations involving KLF4, AKT1, or PIK3CA were not identified in any of 
the 31 adenomatoid tumors in this cohort, indicating that adenomatoid tumors are 
genetically distinct from meningiomas harboring TRAF7 mutations. Nevertheless, TRAF7 
mutations appear to genetically define a group of neoplasms arising from cells whose 
function is lining or wrapping around vital organs such as the brain, peripheral nerves, testis, 
uterus, and fallopian tube.
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TRAF7 mutations have also been identified in a small subset (approximately 2%) of 
malignant mesotheliomas of the pleural cavity.33 Whether these tumors instead represent 
misclassified adenomatoid tumors of the pleural cavity is a distinct possibility. Our recent 
genomic analysis of pathologically confirmed malignant mesotheliomas of the peritoneum 
did not identify any tumors harboring TRAF7 mutation.12 None of the adenomatoid tumors 
of the genital tract in the present cohort were found to harbor alterations in BAP1, NF2, or 
CDKN2A that characterize the vast majority of malignant mesotheliomas. As such, 
mesothelial tumors of the pleural, peritoneal, and other body cavities that are identified to 
harbor TRAF7 mutation should strongly raise the possibility of an adenomatoid tumor, 
especially if alterations typical of malignant mesothelioma or other diagnostic entity are not 
present.
The TRAF7 mutations identified in adenomatoid tumors in this study, as well as those found 
in meningiomas and intraneural perineuriomas,30–32 are all heterozygous missense 
mutations that cluster within a few mutational hotspots in the WD40 repeat domains at the 
C-terminus of the encoded TRAF7 protein. This genetic pattern of heterozygous missense 
mutations that cluster within a limited number of mutational hotspots is strongly suggestive 
that these are activating, gain-of-function mutations, as opposed to inactivating, loss-of-
function events (which are typically truncating mutations scattered throughout a gene 
accompanied by loss of heterozygosity). Thus, TRAF7 is very likely to function as an 
oncogene, rather than a tumor suppressor gene, in these tumor types.
The identification of TRAF7 mutations as the genetic basis for adenomatoid tumors provides 
a potential explanation for why immune dysregulation may contribute to the development of 
these tumors. TRAF7 encodes an E3 ubiquitin ligase that is a member of the family of tumor 
necrosis factor receptor-associated factors (TRAFs). This family of proteins has been 
implicated in regulation of a number of critical immunomodulatory signaling pathways 
involving NF-kB, interferon-regulatory factors (IRFs), c-Jun N-terminal kinases (JNKs), and 
p38 mitogen-activated protein kinases.25,34 We hypothesize that immunosuppression causes 
an abnormal inflammatory state within mesothelial cells lining the peritoneal cavity that 
either causes selective pressure for the acquisition of activating TRAF7 mutation or 
potentiates the oncogenic effect of TRAF7 mutation once acquired, thereby promoting the 
formation of adenomatoid tumors. Although further studies are necessary to completely 
unravel the mechanisms by which TRAF7 mutations lead to the development of intraneural 
perineuriomas, meningiomas, adenomatoid tumors, and perhaps other as-yet unidentified 
tumor types, our study provides the first evidence that activation of NF-kB signaling is likely 
to be at least one of the mechanisms by which TRAF7 mutations cause these specific tumor 
types.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Adenomatoid tumors of the epididymis are defined by somatic TRAF7 mutations. (a) Gross 
photo from patient #1 showing a well-circumscribed nodule in the epididymis. (b) 
Hematoxylin and eosin (H&E) stained section of the tumor. (c) Next-generation sequencing 
reads from the tumor and adjacent uninvolved testis demonstrating a somatic TRAF7 
p.Y538S missense mutation.
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Figure 2. 
Adenomatoid tumors of the fallopian tube are defined by somatic TRAF7 mutations. (a) 
Hematoxylin and eosin stained section from patient #12 showing an ill-defined lesion within 
the paratubal soft tissue. (b) H&E stained section of the tumor. (c) Next-generation 
sequencing reads from the tumor and adjacent uninvolved fallopian tube epithelium 
demonstrating a somatic TRAF7 p.H521R missense mutation.
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Figure 3. 
Adenomatoid tumors of the uterus are defined by somatic TRAF7 mutations. (a) Gross 
photo from patient #21 showing an ill-defined, yellow, multicystic lesion in the uterine body 
with extension into the broad ligament. (b) H&E stained section of the tumor. (c) Next-
generation sequencing reads from the tumor and adjacent uninvolved uterus demonstrating a 
somatic TRAF7 p.S561R missense mutation.
Goode et al. Page 12
Mod Pathol. Author manuscript; available in PMC 2018 May 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. 
Genomic profiling results on 28 patients with adenomatoid tumors of the genital tract. 
Patient age, sex, immune status, tumor location, tumor size, TRAF7 mutation, and other 
somatic mutations identified are shown.
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Figure 5. 
Diagram of human TRAF7 protein with the location of the somatic missense mutations 
identified in the 31 adenomatoid tumors of the genital tract. The mutations all cluster within 
one of five recurrent hotspots in the C-terminal WD40 repeats.
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Figure 6. 
Multiple anatomically and genetically distinct adenomatoid tumors of the uterus and 
fallopian tube in an immunosuppressed patient post-transplant. A 60 year old woman 
(patient #14) who was on immunosuppressive medical therapy following heart and lung 
transplant for congenital heart disease underwent hysterectomy and bilateral salpingo-
oophorectomy for presumed uterine fibroids. Pathology instead revealed multiple 
adenomatoid tumors, one located in the right fallopian tube (a) and three located in the 
uterus (b–d). Genomic analysis identified distinct TRAF7 mutations in each of the four 
tumors.
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Figure 7. 
Western blots on total cell lysate from 293T cells after transfection with empty vector, 
wildtype TRAF7, or TRAF7 harboring three different mutations recurrently found in 
adenomatoid tumors.
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Figure 8. 
Immunohistochemistry for L1 cell adhesion molecule (L1CAM) demonstrates robust 
expression in adenomatoid tumors with the expected membranous staining pattern, whereas 
L1CAM expression is absent in normal mesothelial cells, malignant peritoneal 
mesotheliomas, and multilocular peritoneal inclusion cysts.
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Table 2
L1CAM immunostaining results on normal mesothelium, adenomatoid tumors of the genital tract, and other 
mesothelial lesions of the peritoneal cavity.
Tissue Cases with L1CAM immunostaining Total number of cases % positive for L1CAM
Normal mesothelium 0 7 0%
Adenomatoid tumor 8 8 100%
Malignant peritoneal mesothelioma 0 7 0%
Multilocular peritoneal inclusion cyst 0 6 0%
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